What is NAD+ IV?
NAD+ stands for nicotinamide adenine dinucleotide - a coenzyme present in every single cell of your body. It is not an exotic molecule but one of the most central tools of metabolism, period. NAD+ cycles constantly between its oxidized (NAD+) and reduced form (NADH), shuttling electrons through the major energy pathways: glycolysis, the citric acid cycle and the respiratory chain.
The IV variant here is high-dose - 1000 mg of freeze-dried powder per vial, meant to be dissolved and given as a slow intravenous infusion in the research context. The idea behind it: orally taken NAD+ is largely broken down in the digestive tract before it arrives. An infusion bypasses that path and brings the substance directly into the bloodstream.
NAD+ IV has become popular in the wellness and longevity space. Important and honest: the controlled clinical evidence for the IV form is thin. The molecule itself is exceptionally well researched, the intravenous application by contrast has barely been tested in randomized studies. If you want to read deeper into the fundamentals, see the separate NAD+ lexicon entry. This information is for research and educational purposes only. No medical recommendations.
Comparison
NAD+ in different forms
NAD+ and related products, as described in the TPD lexicon. Tap a card to open its entry.
How it works
NAD+ has two fundamentally different jobs. That is exactly what makes it so interesting.
First, as a redox coenzyme. In glycolysis, the citric acid cycle and at the mitochondrial respiratory chain, NAD+ picks up electrons and releases them again. Without enough NAD+, ATP production stalls - the cell cannot supply its energy efficiently. That is textbook biochemistry, not a speculative mechanism.
Second, as a substrate for NAD+-consuming enzymes. This is where the longevity angle sits. Sirtuins (especially SIRT1) are NAD+-dependent enzymes involved in gene regulation, DNA repair, mitochondrial function and the cellular stress response. PARPs (DNA repair) and CD38 also consume NAD+. Reviews describe that tissue NAD+ levels decline with age and that this drop is preclinically linked to numerous aging processes.
The logic of supplementation: raise NAD+ again so that sirtuins and repair enzymes have more substrate. In animal models this could be shown convincingly. In humans - and especially via the IV route - the evidence is considerably thinner.
Where it acts
Where NAD+ plays a role in studies
Tap a point or a card. Grey = observed, partly in animal studies.
- Heart
Pump function after 1 month higher than on placebo (heart failure, infusion)7
Observed in trials - Blood plasma
Infused NAD+ vanished from plasma at once for 2 hours, with age NAD+ falls there1
Observed in trials - Skin
NAD+ falls with age, in men PARP activity rises at the same time5
Observed in trials - Kidney and urine
More NAD+ and methylnicotinamide in urine after an infusion1
Observed in trials
Known targets2
Compound CHEMBL1234613: three described targets, type of action on each card.
- Gene
- SIRT1
- UniProt
- Q96EB6
- ChEMBL
- CHEMBL4506
- Action
- Needs NAD+ as a cosubstrate and consumes it
- Gene
- PARP1
- UniProt
- P09874
- ChEMBL
- CHEMBL3105
- Action
- Consumes NAD+ when repairing DNA breaks
- Gene
- CD38
- UniProt
- P28907
- ChEMBL
- CHEMBL4660
- Action
- Breaks down NAD+
What you need
NAD+ IV is different from a subcutaneous peptide. It is not injected with an insulin syringe but diluted and slowly infused intravenously. That belongs in skilled hands - an IV infusion is not a home DIY setup.
- The NAD+ vial with the freeze-dried powder (1000 mg)
- Sterile solution to dissolve and dilute (e.g. sterile or bacteriostatic water, then further into a larger infusion carrier solution)
- A sterile infusion set with the ability to set the flow rate slowly
- Alcohol swabs for the vial cap and the puncture site
- A sealable container for used needles
If you are not familiar with IV access: this is the kind of application where experience and sterile technique are decisive.
Application (IV)
Dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
Two things need to be kept cleanly apart here: the basic research on NAD+ as a molecule (strong) and the clinical evidence for the IV application (thin).
On the biology: reviews paint a consistent picture. Covarrubias et al. (2020) describe how NAD+ influences energy metabolism, DNA repair, chromatin and senescence. They also describe how tissue levels fall with age. Imai & Guarente (2014) laid out the NAD+-sirtuin axis early as an aging-relevant mechanism. Rajman et al. (2018) summarize the in vivo evidence for NAD+-boosting molecules - much of it convincing in animal models, more open in humans.
On the IV route specifically: the most important human work is the pilot study by Grant et al. (2019). They infused NAD+ into healthy individuals over 6 hours and tracked plasma and urine metabolites. Surprisingly: in the first 2 hours there was hardly any change in plasma NAD+ - the infused NAD+ was apparently removed from the plasma very quickly and completely and metabolized. Only later did metabolites and excretion products appear. That is a pure pharmacokinetic description, not a proof of efficacy.
Controlled studies demonstrating a clinical benefit of NAD+ IV for anti-aging or wellness endpoints are largely missing. That is the honest state: strong mechanistic foundation, popular practice, but thin outcome evidence specifically for the infusion.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
NAD+ in heart failure after infarctions7
180 adults, 7 days of NAD+ or placebo into a vein on top of standard care
Abstract values 45.44 and 42.44 percent, rounded in the chart. Only pump function differed significantly. One hospital in China, registered in the Chinese trial registry. A study on disease, not on ageing.
How long an infusion took8
Mean minutes, review of client records of one clinic, four days each
On NAD+ participants reported moderate to severe gastrointestinal symptoms, a faster pulse and chest pressure, so the infusion ran slower. All symptoms ended with the infusion. Retrospective review, the authors worked for the provider.
Research status
Where the research stands
Registered trials with NAD+ as an injection or infusion. Precursors such as nicotinamide riboside and NMN as well as NAD+ taken orally, as a patch or a nasal spray are not included. The heart failure trial is in the Chinese registry and is therefore missing here. As of 26 Oct 2026. 10
- Preclinical Animal models of NAD+ in ageing
- Phase 1 1 trial, 0 completed
- Phase 2 no registered trial
- Phase 3 no registered trial
- Approval not yet
Show all 1 trial on a timelineHide timeline
NCT06919328 · 70 participants (planned), started Oct 2024, primary endpoint planned Apr 2025. Tests several agents.
Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 1 trial on safety and pharmacokinetics, not shown as bars.
Side effects
By far the most common observation is pace-dependent: if the infusion runs too fast, flush (heat, redness), pressure in the chest or head, tightness, nausea, abdominal cramps or a general feeling of being unwell appear. These reactions typically ease once you slow the pace down - the reason the infusion should run slowly.
As with any intravenous application, the generic IV risks come on top: pain or irritation at the puncture site, plus an infection risk with poor technique. Sterile technique is not optional here.
Honest on the data: because controlled long-term studies on the IV form are missing, the full side-effect profile under repeated use is not well characterized. What is known is mainly the acute, pace-dependent effects.
Tolerability
Events in the heart failure trial
Out of 100 participants per group, how many had the event over 6 months.
| Event | Placebo | NAD+ as an infusion |
|---|---|---|
| Heart attack7 | 1% | 2% |
| Cardiac death7 | 1% | 1% |
| Stroke7 | 0% | 1% |
| Dizziness during infusion7 | 0% | 1% |
Values from the full text (table 3 and safety section), none of the differences was significant. On placebo there was one case of chest discomfort. Liver and kidney values did not change. In a clinic review NAD+ infusions led to gastrointestinal symptoms, a faster pulse and chest pressure.78
Storage
Store the undissolved powder cool and dark. Once mixed, it keeps for at least 4 to 6 months in the fridge (2 to 8 °C). Only prepare the diluted infusion solution shortly before the infusion and use it promptly.
Shelf life
How long it keeps
Keep the undissolved powder cool and away from light.
Keeps for at least 4 to 6 months. Only prepare the diluted infusion solution shortly before the infusion.
- Keep it dark
- Dissolved: 2 to 8 degrees
- Note the mixing date on the vial